One of the major goals of pharmacogenetics is to elucidate mechanisms and identify patients at increased risk of adverse events (AEs). To date, however, there have been only a few successful examples of this type of approach. In this paper, we describe a retrospective case-control pharmacogenetic study of an AE of unknown mechanism, characterized by elevated levels of serum alanine aminotransferase (ALAT) during long-term treatment with the oral direct thrombin inhibitor ximelagatran. The study was based on 74 cases and 130 treated controls and included both a genome-wide tag single nucleotide polymorphism and large-scale candidate gene analysis. A strong genetic association between elevated ALAT and the MHC alleles DRB1*07 and DQA1*02 was discovered and replicated, suggesting a possible immune pathogenesis. Consistent with this hypothesis, immunological studies suggest that ximelagatran may have the ability to act as a contact sensitizer, and hence be able to stimulate an adaptive immune response.
Introduction
Ximelagatran, marketed as Exanta, was developed for the prevention and treatment of thromboembolism. In patients treated with ximelagatran for more than 35 days, transient elevated levels of serum alanine aminotransferase (ALAT) 43 Â upper limit of normal (ULN) occurred in 6-13% (mean 7.9%) of patients. 
Results
In Phase 1 of EXGEN, 26 613 single nucleotide polymorphisms (SNPs) in 690 selected candidate genes and 266 722 tag SNPs for the genome-wide scan 4 (GWS) were tested for association with elevated ALAT. Calculation of false discovery rates 5 (FDR) for the candidate gene study indicated some evidence for associations over and above what may be expected by chance ( Figure 2 ). However, in the GWS, evidence for genuine associations was weak, possibly due to the larger number of tests performed ( Figure 2 ).
The genetic associations were not adjusted for multiple testing, but were ranked by the minimal P-value across the analyses (P_min) and the top-ranked genes and regions were selected for further analysis. Hence, in Phase 2, additional SNPs (a total of 42 742 SNPs) from the top-ranked 145 candidate genes and from 76 genes or regions from the GWS were genotyped in the same samples, to achieve higher SNP density, or were genotyped by other methods (in the case of HLA-DRB1, -DQA1, -DQB1 and HLA-B).
The lowest P-value obtained from Phase 1 of the candidate gene study was for a SNP (rs2858869) located in the 5 0 -flanking region of HLA-DRB1 (P ¼ 6.0 Â 10
À6
). Reasoning that this association probably resulted from linkage disequilibrium with at least one of the highly polymorphic MHC class II genes in the region, we also genotyped the functional alleles of HLA-DRB1 itself. The method used distinguishes alleles of DRB1 by sequencing the nucleotides that determine the shape of the antigen-binding cleft of the molecule and hence affect the range of peptides that bind into the cleft and are presented to T cells, stimulating the immune response. Among the DRB1 alleles sequenced, the one that best predicts the association of DRB1 with casecontrol status and maximum ALAT was DRB1*0701 (P ¼ 4 Â 10 À5 ). Figure 3 shows the distribution of HLA DRB1*0701 genotype versus maximum ALAT value in all samples.
We also genotyped HLA-DQA1 and -DQB1, which lie close to HLA-DRB1, again using methods that distinguished between the alleles that confer different functional properties on the antigen binding cleft of the DQ heterodimer. False discovery rates for highest-ranked SNPs (ranked by minimum P-values) in Phase 1 of EXGEN. The dashed (red) line shows the FDR analysis of the GWS, demonstrating that nearly 100% of the associations are likely to be due to false discovery, and hence that few of the SNPs are likely to be genuinely associated. The solid (blue) line shows the FDR analysis of the candidate gene study, demonstrating that for the 500 highest-ranked SNPs, the FDR is approximately 70%, suggesting that 30% of these SNPs, representing approximately 145 genes, are likely to be genuinely associated with elevated ALAT. DQA1*02, which commonly lies on the same haplotype as DRB1*0701, 6 was observed to be most strongly associated in this analysis (P ¼ 2 Â 10 À6 ). DQB1 was also associated with case control status (P ¼ 8 Â 10 À5 ), but this association was not explained by any particular allele. However, an estimated 65% of the cases who carried the DRB1*07-DQA1*02 haplotype also carried the DQB1*02 allele.
In general, the increased density of SNPs tested in Phase 2 of EXGEN (including over 2000 SNPs across the entire MHC region 7 ) did not increase the significance of the associations observed, apart from a cluster of additional SNPs with low P-values in the MHC class II region (rs17426385 close to DQA1, P ¼ 7.3 Â 10
À8
and rs9275141, close to DQB1, P ¼ 2.0 Â 10 À7 ). Interestingly, none of these top-ranking SNPs was included in the relatively low-density tag SNP set used for the GWS, and the highest-ranking tag SNP within the MHC region was rs707937, close to VARS2 (P ¼ 1.95 Â 10 À4 Supplementary note 1). There was little evidence for independent associations elsewhere in the MHC region. The 10 genes that were highest-ranked after the completion of EXGEN Phase 1 and Phase 2 studies are listed in Table 1 .
Since only 10 cases and 16 controls were available to test these results for replication, we selected DRB1*07, DQA1*02 and 29 SNPs representing the 20 top-ranked genes for the replication study. Both the DRB1*07 and DQA1*02 alleles showed significant evidence for replication in this cohort (P ¼ 5.97 Â 10 À3 ), as did SNP rs17426385 (P ¼ 1.68 Â 10
À4
) and SNP rs2858869 (P ¼ 1.33 Â 10 À2 ). Only SNP rs17426385 was still statistically significant after Bonferroni correction for multiple testing (P ¼ 0.005). None of the other 27 SNPs tested showed evidence for significant replication. This may be due to a lack of power or because the initial results were false positives. Table 2 shows the distribution of DRB1*07 genotypes in both the EXGEN and replication data sets. A severe case in later development was also genotyped and found to be heterozygous for the DRB1*07-DQA1*02 haplotype.
Neither clinical nor preclinical studies of ximelagatran provided evidence indicative of an immune-mediated mechanism for the elevated ALAT levels. However, allergenicity studies had shown that guinea pigs could be sensitized by subcutaneously administered ximelagatran, and skin reactions were reported in seven of approximately The box-whisker plots (in which the box represents the 25th-75th percentiles of the distribution, the whiskers extend to 5th and 95th percentiles, the central line the median and the small square the mean) demonstrate that the means and distributions of maximum ALAT clearly differ between the genotype groups, with a trend towards increased maximum ALAT with increased copy number of DRB1*0701. Genotypic odds ratio could not be calculated due to zeros in some cells.
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A Kindmark et al 20 individuals exposed to ximelagatran during the manufacturing process (Table 3) . Following the discovery of a genetic association of elevated ALAT with genes involved in the immune response, we initiated a retrospective study to investigate whether patients treated with ximelagatran could generate a positive lymphocyte transformation (LTT) test 8 to indicate the presence of drug-specific immune cells (Table 3 ). Despite the fact that patients might not have been exposed to ximelagatran for over four years, two of 21 patients did demonstrate weakly positive LTT reactions, with maximal stimulation indices of 3.2 (melagatran) and of 2.0 (ximelagatran), respectively. Both of these patients had ALAT-X4ULN and one was heterozygous for the DRB1*07 allele.
In a parallel study, we investigated whether ximelagatran itself could bind to MHC class II molecules in vitro. Using a proprietary competitive binding assay, 9 the company EpiVax (Providence, RI, USA), provided evidence that ximelagatran and its intermediate metabolite melagatran-ethyl, at high concentrations, were able to inhibit the binding of peptides to HLA-DRB1*0701, and not to some other common DRB1 protein alleles ( Figure 4 ).
Discussion
We have demonstrated, and successfully replicated, genetic associations between elevated ALAT during ximelagatran treatment and the MHC class II alleles DRB1*07 and DQA1*02. DRB1*0701 has a protein sequence that is distinct to many other common DRB1 alleles and has a broadly similar geographic distribution to the AE, with a carrier frequency of approximately 11% in Scandinavia, versus 0.3% in Japan. 10, 11 In addition, associations have been 
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A Kindmark et al reported between the DRB1*07-DQA1*02 haplotype and autoimmune hepatitis type 2 12 and with drug-induced liver injury during antituberculosis treatment, 13 although the literature is inconsistent.
Hepatic AEs caused by drugs such as halothane, diclofenac, phenytoin and carbamazepine have been associated with clinical characteristics typical of the adaptive immune system, such as rash, eosinophilia, delay of onset of symptoms and presence of drug-specific antibodies.
14 In the case of ximelagatran, none of these features was present in patients apart from the delay in onset of symptoms. However, the evidence from the guinea pig and LTT studies suggests that ximelagatran may have the ability to act as a contact sensitizer in animals and in man, and hence have the ability to stimulate adaptive immune responses.
Drug-induced adaptive immune responses can arise because the drugs (or more usually their metabolites) bind covalently to protein carriers and act as neoantigens (the hapten hypothesis 15 ), or because the drugs activate immune responses by forming a low-affinity association directly with MHC molecules (the p-i, or p harmacological interaction of drugs with i mmune receptors, hypothesis [16] [17] [18] ). Our finding that ximelagatran and/or its metabolites inhibited binding of peptide to HLA-DRB1*0701 would be consistent with either of these hypotheses being involved in the mechanism of the AE, but since neither ximelagatran, nor any of its metabolites, has ever been found to show any specific covalent binding to proteins, the latter is more likely. In addition, this labile binding is more likely to result in an immune reaction restricted to a T-cell but not to a B-cell response, 18 which would be consistent with the apparent absence of classical signs of hypersensitivity in patients treated with ximelagatran.
Our data further suggest that a biomarker test based on DRB1*07 would have been able to detect patients at risk of the AE with sensitivity of 47% and specificity of 83% (Table  2) . These values compare favourably with recent data on predictive pharmacogenetic safety biomarkers, [19] [20] [21] but also indicate that other factors contribute to susceptibility to the AE. We conclude that pharmacogenetic research of the type used in the EXGEN programme offers great promise for investigation of other serious AEs, and can be of great value both to patients and to pharmaceutical development. 22, 23 Materials and methods Subjects EXGEN. Subjects for the EXGEN study consisted of patients who had previously taken part in clinical studies 1 of ximelagatran (Supplementary Table 1 ). The measurement of serum ALAT levels in these patients was as described previously. 2 Patients who had been treated with ximelagatran during previous clinical studies were defined as cases if they had at least one ALAT measurement X3 Â ULN, controls if they had not had any ALAT elevations 41 Â ULN, and intermediate controls if an elevation had been observed X1 Â ULN but o3 Â ULN. To minimize differences in environmental background, two controls per case were (as far as operationally possible) matched for weight, age, sex, study, country and study site.
LTT study in ximelagatran treated subjects. Subjects for the LTT study consisted of: ximelagatran treated subjects who discontinued at ALAT44 Â ULN, ximelagatran treated subjects who continued treatment after ALAT44 Â ULN (at least once post-randomization) followed by ALAT normalization, ximelagatran treated subjects with no observed ALAT elevation (ALATp1 Â ULN and not exceeding 2 Â baseline value), identified as matched controls to the cases and subjects unexposed to ximelagatran (Supplementary Table 2 ). The study was carried out in approximately 20 centres in Sweden.
LTT study in occupationally exposed subjects. Seven subjects with suspected allergic reactions after occupational exposure to ximelagatran, melagatran, AZE-CBA and NCMC-NCA were included in this study. Another seven healthy volunteers with a history of similar exposure to these chemicals were included as healthy controls.
Replication testing. The independent data set used for replication testing consisted of 26 subjects who took part in the LTT study described above and had not previously been involved in EXGEN. Ten patients (who were defined as cases) had at least one ALAT measurement X4 Â ULN, and 16 patients (who were defined as controls) had ALAT levels that did not rise above 1 Â ULN.
For all these non-interventional clinical studies, the research protocol was approved by the relevant ethics committees and all participants gave written informed consent.
SNP selection
For the first phase of EXGEN (Phase 1), four groups of candidate genes were selected; (i) genes involved in the mechanism of action of ximelagatran, (ii) genes associated in the literature with elevated liver enzymes, (iii) genes derived from additional preclinical studies of ximelagatran and (iv) genes found to be genetically associated with AEs from the literature. Seven hundred and two sequences were identified, corresponding to 690 candidate genes (Supplementary Table 3 ). SNPs were selected for each gene (defined by AstraZeneca's proprietary database and NCBI build 35), and 10 kb flanking sequence. A sliding window approach was used to pick SNPs at a spacing of approximately six SNPs every 10 kb (26 613 SNPs).
The GWS utilized a panel of 266 722 tag SNPs selected from Perlegen Sciences' second-generation SNP map for Caucasian populations. 4 This map consists of 1 586 462 SNPs genotyped in 23 European and American CEPH (Centre d'Etude du Polymorphisme Humain) samples, covering approximately 85% of genes with a density of 41 SNP per 10 kb. SNPs with a minor allele frequency (MAF) of greater than 10% (991 046 SNPs) were selected for construction of a linkage disequilibrium (LD) map using the algorithm described by Carlson et al. 24 A total of 293 709 LD bins were identified of which 153 511 were isolated SNPs. Only 140 198 SNPs were required to tag the non-isolate bins and were therefore selected. In addition, one redundant SNP was selected for each non-isolate bin containing 15 or more SNPs, and each bin with 10 or more SNPs for which there was not a verified working SNP (13 677 SNPs). Common non-synonymous SNPs that had not already been selected from 1 586 462 SNPs (3111 SNPs) as well as the isolate SNPs known to genotype well on Perlegen Science's platform were also selected. This resulted in a total of 266 722 SNPs comprising the Caucasian 250k tag SNP panel.
In the second phase of EXGEN (Phase 2), a further 42 742 SNPs were selected for top-ranking genes/regions using a similar sliding window approach. Chromosomal regions were delimited on the basis of linkage disequilibrium (LD) blocks. 25 This SNP selection included 2270 SNPs that were identified as capturing the majority of common genetic variation across the MHC region 7 and 47 putatively functional SNPs in the MHC class III region, taken from a survey of relevant literature.
SNP genotyping Perlegen
genotyping. Perlegen Sciences performed genotyping in the EXGEN study using their proprietary allele specific hybridization technology. 4 This method used high-density arrays generated by light-directed photolithography together with chemical coupling to synthesize oligonucleotides (25-mers) of specific DNA sequence in predetermined positions on a glass surface. SNPs were detected using a hybridization method, in which array oligonucleotides are hybridized with labelled SNP probes prepared by multiplex PCR from genomic DNA of individual samples. PCR primers were designed using Oligo 6.23 primer design software with high to moderate stringency parameters, using the NCBI Build 35 human genome sequence as the template. Arrays were designed such that each of the SNPs was represented by a set of 40 unique perfect match and mismatch probes (25-mer oligonucleotides), comprising 10 overlapping probe sets. After hybridization and stringent washing the fluorescence intensities of the perfect match features for the reference allele are compared with those for the perfect matches feature for the alternate allele, allowing the three possible SNP genotypes to be distinguished.
To validate the genotype data, 260 SNPs were genotyped by both Perlegen Sciences Inc. (using Perlegen technology) and AstraZeneca (using TaqMan allele specific probes). The SNPs were selected on the basis of availability of commercial assays (Applera), and AstraZeneca performed genotyping according to the manufacturer's instructions using standard TaqMan methodology. Concordance observed was 99.7%.
TaqMan genotyping. In the replication study, AstraZeneca performed genotyping according to the manufacturer's instructions using standard TaqMan methodology. However, the highest-ranking SNP from the EXGEN study, rs17426385, reproducibly failed to genotype in 12-15% of Genome-wide research into Exanta hepatic adverse events subjects. The failure rate was consistent whether samples were genotyped using proprietary Perlegen technology, TaqMan genotyping technology, or a sequencing assay designed by AstraZeneca to cover the SNP region (primers TTCATCCGGCCATAACACA and TGGAATCAATGGCATGT CAA). There appeared to be no correlation between the success rate at the rs17426385 SNP and alleles or success rates of neighbouring SNPs.
We designed a real-time qPCR (based on the same primers) that evaluated the amplification of the region spanning the rs17426385 SNP versus the amplification of a similar product in a housekeeping gene (AAT). We investigated the performance of this assay in 52 samples. Forty-five samples performed successfully in all three assays (TaqMan, sequencing and qPCR). Six samples failed to genotype by all three assays (TaqMan, sequencing and qPCR) despite successful amplification of the control gene in the qPCR assay.
We conclude that the reproducible failure rate of SNP rs17426385 can be explained by a genomic abnormality, probably a deletion/insertion polymorphism (DIP) spanning the SNP region. The location of this DIP is consistent with literature evidence of a complex series of deletions and insertions in the region between DRB1 and DQA1 26 and a null allele of the microsatellite D6S2664, which also lies in this region. 27 We could find no evidence that this DIP affected or biased the distribution of alleles in samples that were successfully genotyped for this SNP.
Genotyping of HLA genes
Typing of the HLA-DRB1 and HLA-B genes was performed by AstraZeneca using the Sequence-Based AlleleSEQR DRB1 and HLA-BAlleleSEQR typing kits, respectively (Atria Genetics, San Francisco, CA, USA), according to the manufacturer's instructions. Resultant DNA sequence traces were interpreted using assign-SBT 3.2.7 software (Conexio Genomics, Applecross, Western Australia). Ambiguities were resolved using the AlleleSEQR HLA-DRB1 GSSP kit (Atria Genetics). AstraZeneca performed genotyping of HLA-DQA1 and -DQB1 using SSP typing (Dynal AllSet þ SSP kit). The resulting PCR products were interpreted using the SSP Tool typing assistant 3.1.0 software (Dynal, Wirral, UK).
Statistical analysis
Single-locus analysis. The primary association analyses used were (i) unmatched case-control two-sided Fisher's exact tests performed for both genotypes and alleles (2 Â 3 and 2 Â 2 tables, respectively) and (ii) Analysis of variance (ANOVA) modelling using log-transformed values of max ALAT, and AUC between 0 and 180 days of treatment. The genotypic and allelic case-control analyses were also repeated with the intermediate controls included in the control category, and the results of the six single locus analyses were summarized to the minimum P-value, P_min.
The analysis of the multi-allelic HLA-DRB1, -DQA1, -DQB1 and HLA-B markers consisted of examining differences in allele frequencies between cases and controls in 2 Â N contingency tables (N is the number of alleles), using the programme CLUMP. 28 The programme assesses the significance in the departure of observed values in a contingency table from the expected values by performing repeated simulations to generate tables having the same marginal totals as the one under consideration. Four statistics were calculated, based on the original 2 Â N contingency table (T1), the original contingency table with allele columns containing small number of cases grouped together (T2), 2 Â 2 tables obtained by comparing one column of the original contingency table against the total of all the other columns (T3), and a 2 Â 2 contingency table designed to maximize the w 2 value (T4). At least 100 000 simulations were performed for each of the contingency tables considered.
Haplotype association analysis. The SNP selection approach undertaken in Phase 1 for the candidate genes and Phase 2 for the selected genes/chromosomal regions from the candidate-gene study and whole genome scan was conducive to multi-SNP haplotype association analysis. Therefore, these genes and chromosomal regions were considered for this analysis. For each gene, LD blocks were defined using the method proposed by Gabriel et al., 25 Population stratification analysis. The Genomic Control 29 and Structure Assessment 30 methods were employed using 2000 randomly selected SNPs from the successfully genotyped SNPs in Phase 1. These showed no substantial evidence for stratification.
Robustness analysis. Matched case-control analyses were performed to assess the robustness of the primary analyses.
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These stratified analyses were performed using conditional logistic regression, where each stratum consisted of one case and one or two controls matched for study, country, sex, age and weight. Results were compared to corresponding unmatched analyses (Supplementary Figure 1) . The matched and unmatched analyses were in close agreement.
The primary associations detected were considered highly robust, since they were detected in many of the phenotypes analysed and were not dependent on the definition of casecontrol status. The case-control definitions defined distinct, well-separated phenotypes and were not dependent on an arbitrary cutoff point.
Multiple testing. For the Phase 1 candidate gene and genome wide scan data, a permutation-based approach was used to calculate a FDR. Phenotypes were randomized between subjects (while maintaining the correlation structure between SNPs) to generate 100 permuted data sets. The single locus association tests described above were then performed and summarized to P_min.
False discovery rates were calculated for different P-value thresholds from the ratio of the number of expected significant tests from the permutations to the observed number of significant tests. The FDRs were then smoothed using the q-value approach. 5 Replication testing. The 20 top-ranked genes were selected for replication testing. Two multi-allelic genes (DRB1 and DQA1) were also tested. SNPs were identified for replication testing using a forwards-selection logistic regression procedure on case-control status. For each gene, SNPs were sequentially included into models until no further SNPs contributed to the association Po0.05, that is, the SNP associations were, to some extent, independent of each other. Where amino-acid changing SNPs in the 20 genes had demonstrated association in the initial study, these were also selected. In total, 29 SNPs were selected and successfully genotyped. Since there were a priori hypotheses as to which alleles were associated with elevated ALAT, one-sided Fisher's exact tests were used to evaluate the significance of replication results where the identity of the associated alleles were consistent with the initial study.
Lymphocyte transformation test
Lymphocyte transformation tests were carried out according to the method of Maria and Victorino. 8 The principle of LTT is that allergy is characterized by the presence of allergenspecific lymphocytes that can be found in peripheral blood. These so-called memory lymphocytes recognize the specific allergen. Allergen-specific lymphocytes can be reactivated in vitro upon exposure to the relevant allergen. The activation leads to cell division and is measured as uptake of 3 Hthymidine. Lymphocytes from subjects exposed to the same allergens, but without symptoms of hypersensitivity, should not exhibit any increase in 3 H-uptake after exposure to the suspected allergen. The LTT is known to have relatively low sensitivity, even for drug allergies, 31 and so a positive result is viewed as being more conclusive than a negative result.
Briefly, venous blood samples (60 ml) were collected in vacuum tubes containing Na-or Li-heparin and transported to Safety Assessment, AstraZeneca Södertälje. For the LTT study, the analysis was performed about 8 h after blood sampling. The blood was diluted 1:1 in cell medium without serum (RPMI 1640 with 10 mM HEPES and 4 mM L-glutamine), and mononuclear cells were isolated on Ficoll (Pharmacia, Sweden) according to the manufacturer's instructions. After isolation, the cells were washed in the same medium and diluted to 1 Â 10 6 /ml in complete cell culture medium (RPMI 1640 with 10 mM HEPES, 4 mM L-glutamine and 10% human AB þ serum). 1 ml of cell suspension was added to each well of two 24-well plates (Costar, Corning, NY, USA), pre-coated as follows: solvent controls (water or 1% DMSO), ximelagatran 500 mg/ml, ximelagatran 250 mg/ml, ximelagatran 125 mg/ml, melagatran 500 mg/ml, melagatran 250 mg/ml, melagatran 125 mg/ml. the same solutions plus indomethacin 1 mg/ml (prostaglandin inhibitor).
Positive control cultures with PHA (phytohemagglutinin), 5 mg/ml, with and without DMSO, were put in a separate cultivation plate with triplicate cultures from each donor.
For the LTT tests of occupationally exposed subjects, methods were essentially the same, except that indomethacin was not used, and the tests also included NCMC-NCA (62.5-250 mg/ml) and AZE-CBA (15.62-62.5 mg/ml).
The plates were incubated in 371C, 5% CO 2 and 90% humidity. After 5 days, 600 ml cell suspension from each well was transferred to new 24-well plates precoated with 3 Hthymidine (Amersham, UK, specific activity 12.7 GBq/mg), 3 mCi/well. These plates were incubated for another 4-6 h at 371C and subsequently the cells were harvested onto glassfibre filters. The filters were dried, treated with scintillator (Beta-plate scint,Wallac, Finland) and counted in a beta counter (MicroBeta 1450, Wallac, Finland). The results from DNA incorporation of 3 
Competition binding assay
The binding assay in use at EpiVax yields an indirect measure of peptide-MHC binding. In this assay soluble HLA molecules were loaded with fluorescently labelled control peptides. The loaded HLA molecules were then incubated with unlabelled experimental small molecules. Once the mixture had reached steady state equilibrium (at 24 h) the HLA molecules (with or without bound labelled control peptides) were captured on an ELISA plate coated with the anti-human DR antibody L243. Time-resolved fluorescence (measuring the remaining fluorescentlylabelled control peptide) was assessed at 615 nm by a Wallac Victor3 unit. Binding of experimental peptides was expressed as experimental fluorescence/control fluorescence*100.
AstraZeneca provided EpiVax with samples of four small molecule drugs: Ximelagatran, Melagatran, Melagatranethyl and Melagatran-OH (the latter was not tested due to problems with solubility). EpiVax was asked to test each of the molecules for their ability to interact with selected HLA molecules (DRB1*0101, DRB1*0401, DRB1*0701 and DRB1*1501) in an allele-specific manner. It is assumed that inhibition of control peptide binding is an indication of binding between the experimental molecules and the binding groove of the HLA molecule. Observed inhibition of control peptide binding may be due to competition for space within the binding groove of the tested HLA. However, it is important to point out that it could also be due to attachment outside of the binding groove that interferes with control peptide binding. EpiVax considers test molecules as 'Non-binders' (that is, demonstrating no significant inhibition) if they inhibit less than 10% of control peptide binding.
Abbreviations

AE
adverse event ALAT alanine aminotransferase DIP deletion/insertion polymorphism EXGEN An explorative pharmacogenetic case-control study, seeking explanation of ximelagatran's pharmacodynamic effects on transient hepatic enzyme elevations during long-term treatment DRB1 the HLA class II DR molecule is a heterodimer consisting of an a (DRA) and a b chain (DRB), of which the latter contains all the polymorphisms specifying the peptide binding specificities. The so-called low-resolution type or two-number code (DRB1*01, and so on) corresponds to all the alleles that encode the DR antigen. The four-number codes (HLA-DRB1*0101, 0102, 0103, and so on) refer to specific DRB1 
